Genistein and daidzein treatment of ovarian cancer cells inhibits invasion and cell migration in a dose-dependent manner through the downregulation of FAK and the PI3K/Akt/GSK signaling pathway and modulates p21 and cyclin D1 expression, related to the presence of ERβ (Chan et al., 2018). The gene discussed is AKT1; the disease is ovarian carcinoma.